<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01951885</url>
  </required_header>
  <id_info>
    <org_study_id>CASE6Z13</org_study_id>
    <nct_id>NCT01951885</nct_id>
  </id_info>
  <brief_title>Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention</brief_title>
  <official_title>Tacrolimus, Mini-dose Methotrexate and Mycophenolate Mofetil Versus Tacrolimus and Methotrexate for the Prevention of Acute Graft-versus-Host-Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized clinical trial studies standard GVHD prophylaxis with tacrolimus and&#xD;
      methotrexate compared to tacrolimus, mycophenolate mofetil and a reduced-dose methotrexate in&#xD;
      patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplant.&#xD;
      Both mycophenolate mofetil and reduced-dose methotrexate, in combination with a calcineurin&#xD;
      inhibitor, have been shown to be safe and effective in GVHD prevention with less toxicity&#xD;
      than standard dose methotrexate. It is not yet known, however, whether this combination of&#xD;
      mycophenolate mofetil and reduced-dose methotrexate with tacrolimus is more effective than&#xD;
      tacrolimus and standard dose methotrexate in preventing GVHD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design This is a prospective randomized trial to determine the effectiveness of&#xD;
      different doses of GVHD prophylaxis on mucositis, engraftment and aGVHD. Study consists of&#xD;
      two study groups of 50 subjects each.&#xD;
&#xD;
      Group A will receive Tac and MTX (15 mg/m2 day +1, 10 mg/m2 day +3, +6, +11). Group B will&#xD;
      receive Tac, Mini-dose MTX (5 mg/m2 on day +1, +3, +6) and MMF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 7, 2014</start_date>
  <completion_date type="Anticipated">August 12, 2021</completion_date>
  <primary_completion_date type="Actual">October 9, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of severe (grade 3-4) mucositis graded according to the World Health Organization (WHO) grading scale</measure>
    <time_frame>Up to day 28</time_frame>
    <description>Patients will be graded three times per week through day 28 of the study. Incidence will be compared through Wilcoxon rank sum tests.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to neutrophil engraftment</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>The number of days to reach a neutrophil count of greater than or equal to 500/ul for three consecutive laboratory values obtained on different days. The day of engraftment will be the first day of the three consecutive laboratory values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to platelet engraftment</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>The number of days to reach a platelet count of greater than or equal to 20,000/ul for three consecutive laboratory values obtained on different days, independent of platelet transfusions the prior 7 days. The day of engraftment will be the first day of the three consecutive laboratory values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of acute GVHD</measure>
    <time_frame>Day 7- Day 100</time_frame>
    <description>Acute GVHD will be estimated using cumulative incidence methods and compared using the Pepe-Mori test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>Date of transplant to date of discharge, assessed up to 1 year</time_frame>
    <description>Hospital stay will be compared between patients in groups A and B using the Wilcoxon rank sum test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of total parenteral nutrition (TPN)</measure>
    <time_frame>Up to day 100</time_frame>
    <description>TPN and 100-day incidence of complications will be compared using the Chi-square test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival defined by Center for International Blood and Marrow Transplant Research (CIBMTR) criteria for individual diseases</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Estimated using the Kaplan-Meier method and compared between the 2 groups using the log-rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival defined by CIBMTR criteria for individual diseases</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Estimated using the Kaplan-Meier method and compared between the 2 groups using the log-rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic GVHD</measure>
    <time_frame>after Day +100, every 3 months</time_frame>
    <description>Chronic GVHD will be graded as mild, moderate, or severe based on the National Institutes of Health Consensus Development Project.The type and duration of immunosuppressive treatment given for cGVHD will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of time on continuous infusion narcotics</measure>
    <time_frame>up to +28 day</time_frame>
    <description>Start and stop dates for the need of continuous IV infusion of narcotics for severe mucositis pain will be recorded. Time on IV infusion will be compared between patients in groups A and B using the Wilcoxon rank sum test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infection</measure>
    <time_frame>Up to day +100</time_frame>
    <description>TPN and 100-day incidence of infection will be compared using a Chi-square test. Infection will be monitored up to one year after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hepatotoxicity</measure>
    <time_frame>Up to day +100</time_frame>
    <description>TPN and 100-day incidence of hepatotoxicity will be compared using a Chi-square test. Hepatotoxicity will be monitored up to one year after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of nephrotoxicity</measure>
    <time_frame>Up to day +100</time_frame>
    <description>TPN and 100-day incidence of nephrotoxicity will be compared using a Chi-square test. Nephrotoxicity will be monitored up to one year after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of pulmonary toxicity</measure>
    <time_frame>Up to day +180</time_frame>
    <description>TPN and 180-day incidence of pulmonary toxicity will be compared using a Chi-square test. Pulmonary toxicity will be monitored up to one year after transplantation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Chimerism results</measure>
    <time_frame>Up to one year</time_frame>
    <description>Donor chimerism will be assessed by analysis of single-tandem repeats on whole marrow and in lymphocyte enriched or sorted CD3+ T cells and CD33+ granulocytes. Blood will be obtained for donor chimerism &quot;Bone Marrow Engraftment analysis&quot; at approximately 1, 2, 3, 6, 9 and 12 months or as clinically indicated.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Biphenotypic Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Myeloproliferative Neoplasm</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Hodgkins Disease</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Group A (tacrolimus, methotrexate)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive tacrolimus IV over 24 hours beginning on day -1 (or tacrolimus orally beginning on day -3) and then PO BID after engraftment with a taper from day 100 to day 180 (in the absence of GVHD). Patients also receive methotrexate IV on days 1, 3, 6, and 11.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (tacrolimus, methotrexate, mycophenolate mofetil)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive tacrolimus as in group A and methotrexate (low dose) IV on days 1, 3, and 6. Patients also receive oral mycophenolate mofetil BID beginning on day 1, with a taper from day 45 to day 100 (in the absence of GVHD).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>Tacrolimus 0.03 mg/kg/day beginning day -1 or tacrolimus 0.03mg/kg/dose BID orally beginning on day -3. If Tac is administered intravenously, it will be given over 24 hours and will be converted to oral administration 2 times a day when the patient has engrafted and/or can tolerate oral medication. Levels of Tac will be obtained to maintain a recommended target serum level of 5-12 ng/mL</description>
    <arm_group_label>Group A (tacrolimus, methotrexate)</arm_group_label>
    <arm_group_label>Group B (tacrolimus, methotrexate, mycophenolate mofetil)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>MTX 15mg/m2 IV on day +1, followed by 10mg/m2 on day +3, +6, +11. If patient &lt; 10 kg then MTX will be given at 0.5 mg/kg IV on day +1. Then MTX will be given at 0.33 mg/kg on days +3, +6 and +11.</description>
    <arm_group_label>Group A (tacrolimus, methotrexate)</arm_group_label>
    <other_name>amethopterin</other_name>
    <other_name>Folex</other_name>
    <other_name>methylaminopterin</other_name>
    <other_name>Mexate</other_name>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Patients will receive Mycophenolate beginning on day +1. Patients &gt;40 kg will receive Mycophenolate 1000 mg twice a day. Mycophenolate should be given orally twice a day. IV formulation may be used if the patient cannot tolerate oral route. Patients &lt; 40 kg will receive MMF 45 mg/kg/day (15 mg/kg three times a day). MMF may be given orally or intravenously as per institutional protocol</description>
    <arm_group_label>Group B (tacrolimus, methotrexate, mycophenolate mofetil)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate (low dose)</intervention_name>
    <description>MTX 5mg/m2 IV on day +1, +3, +6. If patient&lt;10 kg MTX will be given at 0.17 mg/kg on day +1, +3, and +6.</description>
    <arm_group_label>Group B (tacrolimus, methotrexate, mycophenolate mofetil)</arm_group_label>
    <other_name>amethopterin</other_name>
    <other_name>Folex</other_name>
    <other_name>methylaminopterin</other_name>
    <other_name>Mexate</other_name>
    <other_name>MTX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have one of the following documented diseases:&#xD;
&#xD;
               -  Chronic myelogenous leukemia&#xD;
&#xD;
               -  Chronic lymphocytic leukemia&#xD;
&#xD;
               -  Multiple myeloma&#xD;
&#xD;
               -  Myelodysplasia&#xD;
&#xD;
               -  Myeloproliferative disorder&#xD;
&#xD;
               -  Non-Hodgkin's lymphoma&#xD;
&#xD;
               -  Hodgkin's disease&#xD;
&#xD;
               -  Acute myelogenous leukemia&#xD;
&#xD;
               -  Acute lymphoblastic leukemia&#xD;
&#xD;
               -  Acute biphenotypic leukemia&#xD;
&#xD;
          -  Patients must be undergoing a myeloablative allogeneic hematopoietic cell transplant&#xD;
             with one of the following conditioning regimens:&#xD;
&#xD;
               -  Busulfan (≥ 12.8 mg/kg IV or PO) and cyclophosphamide (≥ 120 mg/kg)&#xD;
&#xD;
                  --- Busulfan dose may be adjusted according to pharmacokinetics targeting a daily&#xD;
                  AUC of 5000 μmol-min/L, per institution standard of practice.&#xD;
&#xD;
               -  Total body irradiation (TBI) (≥ 1200 cGy) and etoposide (60 mg/kg)&#xD;
&#xD;
               -  TBI (≥ 1200 cGy) and cyclophosphamide (120 mg/kg)&#xD;
&#xD;
          -  Patient must have achieved and be in complete morphologic remission prior to starting&#xD;
             conditioning regimen&#xD;
&#xD;
          -  Patient's donor must be a related or unrelated human leukocyte antigen (HLA) 8/8&#xD;
             allele-level match (HLA-A, B, C and DRB1)&#xD;
&#xD;
          -  Adult patients must have an Eastern Cooperative Oncology Group (ECOG) performance&#xD;
             status of 0 or 1; pediatric patients must have Lansky score ≥ 60%&#xD;
&#xD;
          -  Patients must have a life expectancy of 100 days&#xD;
&#xD;
          -  Patients must sign written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have undergone any prior transplant&#xD;
&#xD;
          -  Patients who are seropositive for human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Patients with any medical illness or concurrent psychiatric illness which, in the&#xD;
             investigators' opinion, cannot be adequately controlled with appropriate therapy&#xD;
&#xD;
          -  Patients who are pregnant or lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Betty Hamilton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 24, 2013</study_first_submitted>
  <study_first_submitted_qc>September 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2013</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Leukemia, Biphenotypic, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 5, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT01951885/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 16, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT01951885/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

